NKX019
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin
Conditions
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
Trial Timeline
Aug 20, 2021 → Dec 1, 2038
NCT ID
NCT05020678About NKX019
NKX019 is a phase 1 stage product being developed by Nkarta for Lymphoma, Non-Hodgkin. The current trial status is active. This product is registered under clinical trial identifier NCT05020678. Target conditions include Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Non-Hodgkin were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05020678 | Phase 1 | Active |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin